drugset
drugset / Trial / NCT03105596

Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

NCT03105596 ↗

Phase 2 Unknown 46 enrolled Peking University
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).

Timeline

Start
2017-04-11
Primary completion
2018-09-30
Completion
2019-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 20 mg Oral
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule 0.4 g Other
Background Cisplatin Other / unclassified 25 mg/m2 Other
Background Dexamethasone Small molecule 10 mg Other
Background Etoposide Small molecule 60 mg/m2 Other
Background Ifosfamide Small molecule 1000 mg/m2 Other

Indications

B-cell non-Hodgkin lymphoma